Abstract LB-155: Rapid patient derived xenograft avatars that consider tumor heterogeneity for prediction of cancer immunotherapy responses in metastatic renal cell carcinoma patients
Authors: Mario Cepeda, Matthew Lowerison, Cindy Liu, Yarolslav Fedyshyn, Vidhu Joshi, Paras Shah, John Cheville, R. Houston Thompson, Boorjian Stephen, Bradley Leibovich, Haidong Dong, Hon S. Leong
Journal: Cancer Research (2018)

Abstract INTRODUCTION AND OBJECTIVES: Patient responses to cancer immunotherapy such as checkpoint inhibitor drugs vary greatly between patients and there remains no biomarker to predict sensitivity to these drugs. We describe a patient derived xenograft (PDX) avatar system that predicts cancer immunotherapy responses in the context of tumor heterogeneity within 8-10 days. This avatar model preserves the original tumor microenvironment and tumor infiltrating lymphocytes (TILs) at a high tumor take rate for evaluation of various immunotherapy drugs. This prediction model also involves tumor infiltrating lymphocyte isolation and primary cell generation for confirming the immunotherapy response in vitro. This PDX avatar platform generates rapid actionable information and readily identifies patients that would maximally benefit from checkpoint inhibitor therapies in a phenotype-based manner. METHODS: Tissue from patients that underwent a nephrectomy for RCC or metastasectomy were engrafted into the chorioallantoic membrane of avian embryos with a portion used for TIL isolation and primary cell generation. PD-1 and PD-L1 checkpoint inhibitors were intravenously injected and high frequency ultrasound imaging and immunophenotyping was used to quantitate changes in tumor volume, vascularity, and TIL expansion in all treatment groups. Isolated TILs were expanded and co-cultured with respective primary cells to confirm and examine immunotherapy response at a molecular level. RESULTS: Patient PDXs demonstrated heterogeneous responses to immunotherapy that relates to presence and expansion of TILs after checkpoint inhibitor injection. Patient #1 demonstrated the greatest response with a &amp;gt;50% reduction in tumor volume and 4X expansion of T-cells over 8 days of treatment. Patient #2 demonstrated intratumoral heterogeneities in terms of tumor volume change after checkpoint inhibitors treatment despite TIL expansion in all treatment groups. Patient #3 showed no response that correlated to lack of TILs in the PDX. In vitro expansion of TILs and co-culture with primary cell line demonstrated a specific immune response via INF-gamma release and changes in immunomodulatory molecules. CONCLUSIONS: This PDX system preserves TILs and permits rapid large scale prediction of tumor specimens to various systemic therapy agents such as checkpoint inhibitors without the need for humanized models. This avatar system is a useful tool to rapidly predict and examine response to checkpoint inhibitors on a per-patient basis to improve the assignment of cancer immunotherapies to specific RCC patients. Citation Format: Mario Cepeda, Matthew Lowerison, Cindy Liu, Yarolslav Fedyshyn, Vidhu Joshi, Paras Shah, John Cheville, R. Houston Thompson, Boorjian Stephen, Bradley Leibovich, Haidong Dong, Hon S. Leong. Rapid patient derived xenograft avatars that consider tumor heterogeneity for prediction of cancer immunotherapy responses in metastatic renal cell carcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-155.